According to Health Yuan, on March 20, Health Yuan Pharmaceutical Group and Bayer signed an exclusive license agreement for the development, commercialization and production of small molecule inhibitors in China. This is also the first time that Health Yuan has introduced innovative drug pipelines in the respiratory field from a leading global multinational company.
健康元与拜耳达成小分子抑制剂独家授权许可合作
Health Yuan and Bayer reach exclusive licensing cooperation for small molecule inhibitors
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.